{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:24:36Z","timestamp":1774070676193,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Shanghai Municipal Commission of Health and Family Planning","award":["201440019"],"award-info":[{"award-number":["201440019"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["15DZ1208002"],"award-info":[{"award-number":["15DZ1208002"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC0901504"],"award-info":[{"award-number":["2016YFC0901504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clim.2019.05.006","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T18:07:49Z","timestamp":1557425269000},"page":"142-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Inhibition of ROCK activity regulates the balance of Th1, Th17 and Treg cells in myasthenia gravis"],"prefix":"10.1016","volume":"203","author":[{"given":"Jie","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Shan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Guo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong-Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2019.05.006_bb0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2019.05.006_bb0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clim.2019.05.006_bb0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis [mdash] autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clim.2019.05.006_bb0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23\u2013IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00011-009-0087-6","article-title":"Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17\/Th1 to a Th2 and FoxP3 + regulatory T-cell profile","volume":"59","author":"Yang","year":"2010","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.clim.2019.05.006_bb0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/21541248.2016.1173770","article-title":"Made to measure - keeping Rho kinase at a distance","volume":"7","author":"Truebestein","year":"2016","journal-title":"Small GTPases"},{"key":"10.1016\/j.clim.2019.05.006_bb0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri2606","article-title":"Rho family GTPases and their regulators in lymphocytes","volume":"9","author":"Tybulewicz","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0040","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.12688\/f1000research.7522.1","article-title":"The RhoA-ROCK pathway in the regulation of T and B cell responses","volume":"5","author":"Ricker","year":"2016","journal-title":"F1000research"},{"key":"10.1016\/j.clim.2019.05.006_bb0045","doi-asserted-by":"crossref","first-page":"26775","DOI":"10.1074\/jbc.M113.483743","article-title":"Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling","volume":"288","author":"Apostolidis","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2019.05.006_bb0050","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI42856","article-title":"Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice","volume":"120","author":"Biswas","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.clim.2019.05.006_bb0055","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","article-title":"Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism","volume":"111","author":"Zaninzhorov","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2019.05.006_bb0060","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4049\/jimmunol.178.3.1938","article-title":"Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus","volume":"178","author":"Li","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0065","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.37934","article-title":"Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus","volume":"65","author":"Isgro","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2019.05.006_bb0070","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/annrheumdis-2016-209850","article-title":"Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE","volume":"76","author":"Rozo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2019.05.006_bb0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaut.2017.12.009","article-title":"Critical role of ROCK2 activity in facilitating mucosal CD4(+) T cell activation in inflammatory bowel disease","volume":"89","author":"Yang","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2019.05.006_bb0080","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","article-title":"Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats","volume":"172","author":"Baggi","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0085","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/imm.12322","article-title":"Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses","volume":"143","author":"Yao","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.clim.2019.05.006_bb0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12974-015-0334-4","article-title":"Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway","volume":"12","author":"Wang","year":"2015","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.clim.2019.05.006_bb0095","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/eji.201142088","article-title":"Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity","volume":"42","author":"Li","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clim.2011.04.013","article-title":"Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms","volume":"141","author":"Mu","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-med-051914-022120","article-title":"Rho kinases in autoimmune diseases","volume":"67","author":"Pernis","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.clim.2019.05.006_bb0110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T Cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann. New York Acad. Sci."},{"key":"10.1016\/j.clim.2019.05.006_bb0115","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/383787a0","article-title":"Functional diversity of helper T lymphocytes","volume":"383","author":"Abbas","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.clim.2019.05.006_bb0120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.expneurol.2009.09.022","article-title":"T-bet deficiency decreases susceptibility to experimental myasthenia gravis","volume":"220","author":"Liu","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.clim.2019.05.006_bb0125","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0130","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.4049\/jimmunol.162.7.3775","article-title":"Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis","volume":"162","author":"Zhang","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.2012.06791.x","article-title":"Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17","volume":"1274","author":"Gradolatto","year":"2012","journal-title":"Ann. New York Acad. Sci."},{"key":"10.1016\/j.clim.2019.05.006_bb0140","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/eji.200737973","article-title":"CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity","volume":"38","author":"Bai","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.clim.2019.05.006_bb0150","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-\u03b3 and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0155","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1172\/JCI116610","article-title":"T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits","volume":"92","author":"Manfredi","year":"1993","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.clim.2019.05.006_bb0160","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1212\/WNL.50.4.1045","article-title":"T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis","volume":"50","author":"Wang","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2019.05.006_bb0165","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/507418a","article-title":"Immunology: a tolerant approach","volume":"507","author":"Garber","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clim.2019.05.006_bb0170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1586\/1744666X.2015.1047345","article-title":"The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics","volume":"11","author":"Alahgholi-Hajibehzad","year":"2015","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13591","article-title":"An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor\u2013positive myasthenia gravis patients","volume":"1413","author":"Villegas","year":"2018","journal-title":"Ann. New York Acad. Sci."},{"key":"10.1016\/j.clim.2019.05.006_bb0180","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/eji.200939792","article-title":"Expansion of regulatory T cells via IL-2\/anti-IL-2 mAb complexes suppresses experimental myasthenia","volume":"40","author":"Liu","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2019.05.006_bb0185","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.clim.2019.05.006_bb0190","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mcn.2016.05.001","article-title":"ROCK inhibitor abolishes the antibody response in experimental autoimmune myasthenia gravis","volume":"74","author":"Li","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.clim.2019.05.006_bb0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nri2958","article-title":"Genomic views of STAT function in CD4+ T helper cell differentiation: new technology brings new insights and new questions","volume":"11","author":"O'Shea","year":"2011","journal-title":"Nat. Rev. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661619301561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661619301561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T12:15:52Z","timestamp":1694866552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661619301561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":39,"alternative-id":["S1521661619301561"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2019.05.006","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of ROCK activity regulates the balance of Th1, Th17 and Treg cells in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2019.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}